TCRT

Alaunos Therapeutics, Inc.

4.20 USD
-0.02 (-0.47%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Alaunos Therapeutics, Inc. stock is down -40% since 30 days ago. The next earnings date is Aug 12, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 26.32% of the previous 18 July’s closed higher than June.

About Alaunos Therapeutics, Inc.

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR. The company was formerly known as ZIOPHARM Oncology, Inc.